We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Cullinan Oncology Inc
1 own
1 watching
Current Price
$11.77
$-0.14
(-1.18%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
538.4M
52-Week High
15.89
52-Week Low
7.3
Average Volume
0.35M
Dividend Yield
--
P/E Ratio
--
Market Capitalization538.4M52-Week High15.8952-Week Low7.3Average Volume0.35MDividend Yield--P/E Ratio--What does the Cullinan Oncology Inc do?
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company s lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Cullinan Oncology Inc make?
News & Events about Cullinan Oncology Inc.
Globe Newswire
12days ago
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc.(Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announcedthe U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ...
Globe Newswire
6 months ago
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan Oncology) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its Chief Financial Officer, Jeff Trigilio, ...
Globe Newswire
8 months ago
Updated data from Phase 1/2a study show median duration of response greater than 21 months and median progression-free survival of 12 months at 100 mg BID dose Confirmed overall response rate of 41% at 100 mg BID dose Continued favorable safety and tolerability profile observed in heavily pre-...
Globe Newswire
8 months ago
Meeting to highlight updated data from the Phase 1/2a study of CLN-081 CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today ...
Globe Newswire
8 months ago
Taiho obtains exclusive global rights to CLN-081/TAS6417 outside the U.S.; in the U.S., Taiho and Cullinan Oncology to jointly develop and co-commercialize CLN-081/TAS6417 Cullinan Oncology will receive an upfront cash payment of $275 million, with potential to receive up to an additional $130 ...
Frequently Asked Questions
Frequently Asked Questions
What is Cullinan Oncology Inc share price today?
Can Indians buy Cullinan Oncology Inc shares?
How can I buy Cullinan Oncology Inc shares from India?
Can Fractional shares of Cullinan Oncology Inc be purchased?
What are the documents required to start investing in Cullinan Oncology Inc stocks?
What is today’s traded volume of Cullinan Oncology Inc?
What is today’s market capitalisation of Cullinan Oncology Inc?
What is the 52-Week High and Low Range of Cullinan Oncology Inc?
What percentage is Cullinan Oncology Inc down from its 52-Week High?
What percentage is Cullinan Oncology Inc up from its 52-Week Low?
Current Price
$11.77
$-0.14
(-1.18%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.